These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17762578)

  • 41. Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC).
    Schmid-Bindert G
    Target Oncol; 2013 Mar; 8(1):15-26. PubMed ID: 23371029
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
    Gubbi A; Kendrick JE; Finkler NJ
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emerging therapies: angiogenesis inhibitors for ovarian cancer.
    Jackson AL; Eisenhauer EL; Herzog TJ
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):331-46. PubMed ID: 26001052
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Beyond bevacizumab: antiangiogenic agents.
    Rogosin S; Sandler AB
    Clin Lung Cancer; 2012 Sep; 13(5):326-33. PubMed ID: 22297207
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bevacizumab and ovarian cancer.
    Sato S; Itamochi H
    Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.
    Tao X; Sood AK; Deavers MT; Schmeler KM; Nick AM; Coleman RL; Milojevic L; Gershenson DM; Brown J
    Gynecol Oncol; 2009 Sep; 114(3):431-6. PubMed ID: 19524286
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
    Han ES; Wakabayashi M; Leong L
    Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
    Manegold C
    Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of bevacizumab in advanced epithelial ovarian cancer.
    Kroep JR; Nortier JW
    Curr Pharm Des; 2012; 18(25):3775-83. PubMed ID: 22591420
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiangiogenic therapies in ovarian cancer.
    Reinthaller A
    Memo; 2016; 9(3):139-143. PubMed ID: 27752291
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiangiogenic therapy for cancer: an update.
    Al-Husein B; Abdalla M; Trepte M; Deremer DL; Somanath PR
    Pharmacotherapy; 2012 Dec; 32(12):1095-111. PubMed ID: 23208836
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current status of bevacizumab in advanced ovarian cancer.
    Tomao F; Papa A; Rossi L; Caruso D; Panici PB; Venezia M; Tomao S
    Onco Targets Ther; 2013; 6():889-99. PubMed ID: 23901283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research.
    Gadducci A; Lanfredini N; Sergiampietri C
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):113-28. PubMed ID: 26126494
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Angiogenesis as a strategic target for ovarian cancer therapy.
    Spannuth WA; Sood AK; Coleman RL
    Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current status on biologic therapies in the treatment of epithelial ovarian cancer.
    Han ES; Lin P; Wakabayashi M
    Curr Treat Options Oncol; 2009 Apr; 10(1-2):54-66. PubMed ID: 19381822
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent concepts of antiangiogenic therapy.
    Konno H; Yamamoto M; Ohta M
    Surg Today; 2010 Jun; 40(6):494-500. PubMed ID: 20496129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.